Background: Polymyalgia Rheumatica (PMR) is a common inflammatory rheumatic
condition in people aged≥ 50 years with incidence peaking at 70–80 years. PMR is …

ABSTRACT Introduction: Polymyalgia rheumatica (PMR), a common disease in individuals
older than 50 in the western world, is characterized by bilateral inflammatory pain involving …

Objective. To identify the instruments used to assess polymyalgia rheumatica (PMR) in
published studies. Methods. A systematic literature review of clinical trials and longitudinal …

Objectives To evaluate efficacy and safety of tocilizumab as first line therapy in patients with
recent Polymyalgia Rheumatica (PMR). Methods Patients with recent PMR fulfilling the …

Polymyalgia rheumatica (PMR) is an inflammatory condition of unknown etiology
characterized by aching and stiffness in the shoulder and in the pelvic girdles and neck. In …

Guidelines on management of polymyalgia rheumatica (PMR) recommend early introduction
of methotrexate (MTX), especially in patients with worse prognosis, although evidence on …

Background the mainstay of treatment of polymyalgia rheumatica (PMR) is oral
glucocorticoids, but randomized controlled trials of treatment are lacking. As a result, there is …

Objectives The efficacy of anti-IL-6 receptors such as tocilizumab (TCZ) was demonstrated in
patients with PMR in two recent randomized controlled trials. The objective of this …

In an American study, the lifetime risk of polymyalgia rheumatica (PMR), when compared to
that of rheumatoid arthritis (RA), was similar in men and about one third lower in women [1] …

Glucocorticoids constitute the cornerstone of therapy in the management of polymyalgia
rheumatica (PMR)[1]. Nevertheless, their use in a disease that affects people≥ 50 years of …